Carvedilol recovers normal blood pressure variability in rats with myocardial infarction

Autonomic Neuroscience: Basic and Clinical

Volumn 177, Issue 2, 2013, Pages 231-236

  Dantas, Eduardo Miranda ^a   Pimentel, Enildo Broetto ^a   Andreão, Rodrigo Varejão ^b   Cichoni, Bruna Sgaria ^a   Gonçalves, Christine Pereira ^a   Zaniqueli, Divanei dos Anjos ^a   Baldo, Marcelo Perim ^a   Rodrigues, Sérgio Lamêgo ^a   Mill, José Geraldo ^a  

^a FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^b INSTITUTO FEDERAL DO ESPÍRITO SANTO   (Brazil)

Author keywords

Arterial blood pressure; Autonomic nervous system; Beta blocker therapy; Power spectral analysis

Indexed keywords

CARVEDILOL; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; BODY WEIGHT; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; HEART INFARCTION; HEART RATE VARIABILITY; LEFT CORONARY ARTERY; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ARTERIAL BLOOD PRESSURE; AUTONOMIC NERVOUS SYSTEM; BETA-BLOCKER THERAPY; BLOOD PRESSURE VARIABILITY; BPV; CARV; CARVEDILOL; HEART RATE VARIABILITY; HF; HIGH FREQUENCY; HRV; LF; LOW FREQUENCY; MI; MYOCARDIAL INFARCT; PLAC; PLACEBO; POWER SPECTRAL ANALYSIS; SHAM OPERATED; SO; VERY LOW FREQUENCY; VLF;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BLOOD PRESSURE; CARBAZOLES; HEART RATE; MALE; MYOCARDIAL INFARCTION; PROPANOLAMINES; RANDOM ALLOCATION; RATS; RATS, WISTAR; RECOVERY OF FUNCTION;

EID: 84883804628     PISSN: 15660702     EISSN: 18727484     Source Type: Journal    
DOI: 10.1016/j.autneu.2013.05.007     Document Type: Article

References (44)

1. Akselrod S., Gordon D., Madwed J.B., Snidman N.C., Shannon D.C., Cohen R.J. Hemodynamic regulation: investigation by spectral analysis. Am. J. Physiol. 1985, 249(4 Pt 2):H867-H875.
2. Bertera F.M., del Mauro J.S., Chiappetta D., Polizio A.H., Buontempo F., Taira C.A., Hocht C. Enantioselective pharmacokinetic and pharmacodynamic properties of carvedilol in spontaneously hypertensive rats: focus on blood pressure variability. Naunyn Schmiedebergs Arch. Pharmacol. 2012, 385(3):325-335.
3. Bullinga J.R., Alharethi R., Schram M.S., Bristow M.R., Gilbert E.M. Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure. J. Card. Fail. 2005, 11(9):693-699.
4. Caruana M.P., Lahiri A., Cashman P.M., Altman D.G., Raftery E.B. Effects of chronic congestive heart failure secondary to coronary artery disease on the circadian rhythm of blood pressure and heart rate. Am. J. Cardiol. 1988, 62(10 Pt 1):755-759.
5. Dantas E.M., Sant'Anna M.L., Andreao R.V., Goncalves C.P., Morra E.A., Baldo M.P., Rodrigues S.L., Mill J.G. Spectral analysis of heart rate variability with the autoregressive method: what model order to choose?. Comput. Biol. Med. 2012, 42(2):164-170.
6. Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001, 357(9266):1385-1390.
7. Detollenaere M.S., Duprez D.A., de Buyzere M.L., Vandekerckhove H.J., de Backer G.G., Clement D.L. 24hour ambulatory blood pressure variability and cardiac parasympathetic function 2 and 6weeks after acute myocardial infarction. Clin. Auton. Res. 1993, 3(4):255-259.
8. Di Rienzo M., Parati G., Castiglioni P., Omboni S., Ferrari A.U., Ramirez A.J., Pedotti A., Mancia G. Role of sinoaortic afferents in modulating BP and pulse-interval spectral characteristics in unanesthetized cats. Am. J. Physiol. 1991, 261(6 Pt 2):H1811-H1818.
9. Francis J., Weiss R.M., Wei S.G., Johnson A.K., Felder R.B. Progression of heart failure after myocardial infarction in the rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001, 281(5):R1734-R1745.
10. Gaziano T.A., Bitton A., Anand S., Abrahams-Gessel S., Murphy A. Growing epidemic of coronary heart disease in low- and middle-income countries. Curr. Probl. Cardiol. 2010, 35(2):72-115.
11. Giles T.D., Kerut E.K., Roffidal L.E., Jones R., Given M.B., Hutchinson H., Tresznewsky O. The influence of dose of angiotensin I-converting enzyme inhibitor on systolic blood pressure variability in heart failure: a substudy of the Assessment of Treatment with Lisinopril and Survival in heart failure (ATLAS) trial. Blood Press Monit. 2001, 6(2):81-84.
12. Gunnar R.M., Bourdillon P.D., Dixon D.W., Fuster V., Karp R.B., Kennedy J.W., Klocke F.J., Passamani E.R., Pitt B., Rapaport E. ACC/AHA guidelines for the early management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (subcommittee to develop guidelines for the early management of patients with acute myocardial infarction). Circulation 1990, 82(2):664-707.
13. Guzzetti S., Cogliati C., Turiel M., Crema C., Lombardi F., Malliani A. Sympathetic predominance followed by functional denervation in the progression of chronic heart failure. Eur. Heart J. 1995, 16(8):1100-1107.
14. Julien C., Zhang Z.Q., Cerutti C., Barres C. Hemodynamic analysis of arterial pressure oscillations in conscious rats. J. Auton. Nerv. Syst. 1995, 50(3):239-252.
15. Kara T., Narkiewicz K., Somers V.K. Chemoreflexes-physiology and clinical implications. Acta Physiol. Scand. 2003, 177(3):377-384.
16. Kardos A., Halmai L., Rudas L., Csanady M. Changes in blood pressure and heart period variability in patients with recent acute myocardial infarction. Clin. Sci. (Lond.) 1996, (91 Suppl.):52-55.
17. Kruger C., Kalenka A., Haunstetter A., Schweizer M., Maier C., Ruhle U., Ehmke H., Kubler W., Haass M. Baroreflex sensitivity and heart rate variability in conscious rats with myocardial infarction. Am. J. Physiol. 1997, 273(5 Pt 2):H2240-H2247.
18. La Rovere M.T., Bigger J.T., Marcus F.I., Mortara A., Schwartz P.J. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998, 351(9101):478-484.
19. Magagnin V., Bassani T., Bari V., Turiel M., Maestri R., Pinna G.D., Porta A. Non-stationarities significantly distort short-term spectral, symbolic and entropy heart rate variability indices. Physiol. Meas. 2011, 32(11):1775-1786.
20. Malliani A., Pagani M., Lombardi F., Cerutti S. Cardiovascular neural regulation explored in the frequency domain. Circulation 1991, 84(2):482-492.
21. Mancia G., Frattola A., Parati G., Santucciu C., Ulian L. Blood pressure variability and organ damage. J. Cardiovasc. Pharmacol. 1994, (24 Suppl. A):S6-S11.
22. Martinka P., Fielitz J., Patzak A., Regitz-Zagrosek V., Persson P.B., Stauss H.M. Mechanisms of blood pressure variability-induced cardiac hypertrophy and dysfunction in mice with impaired baroreflex. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005, 288(3):R767-R776.
23. Mill J.G., Leite D.V., Novaes M.A., Lima-Pereira F.E., Vassallo D.V. Propranolol reduces myocardial hypertrophy in the right cardiac chambers after infarction in rats. Braz. J. Med. Biol. Res. 1992, 25(8):865-869.
24. Mittal B.V., Singh A.K. Hypertension in the developing world: challenges and opportunities. Am. J. Kidney Dis. 2010, 55(3):590-598.
25. Mortara A., La Rovere M.T., Pinna G.D., Maestri R., Capomolla S., Cobelli F. Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure. J. Am. Coll. Cardiol. 2000, 36(5):1612-1618.
26. Mostarda C., Rodrigues B., Vane M., Moreira E.D., Rosa K.T., Moraes-Silva I.C., Lacchini S., Casarini D.E., De A.K., Irigoyen M.C. Autonomic impairment after myocardial infarction: role in cardiac remodelling and mortality. Clin. Exp. Pharmacol. Physiol. 2010, 37(4):447-452.
27. Notarius C.F., Butler G.C., Ando S., Pollard M.J., Senn B.L., Floras J.S. Dissociation between microneurographic and heart rate variability estimates of sympathetic tone in normal subjects and patients with heart failure. Clin. Sci. (Lond.) 1999, 96(6):557-565.
28. Ohte N., Narita H., Iida A., Fukuta H., Iizuka N., Hayano J., Kuge Y., Tamaki N., Kimura G. Cardiac beta-adrenergic receptor density and myocardial systolic function in the remote noninfarcted region after prior myocardial infarction with left ventricular remodelling. Eur. J. Nucl. Med. Mol. Imaging 2012, 39(8):1246-1253.
29. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., Shusterman N.H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N. Engl. J. Med. 1996, 334(21):1349-1355.
30. Packer M., Colucci W.S., Sackner-Bernstein J.D., Liang C.S., Goldscher D.A., Freeman I., Kukin M.L., Kinhal V., Udelson J.E., Klapholz M., Gottlieb S.S., Pearle D., Cody R.J., Gregory J.J., Kantrowitz N.E., Lejemtel T.H., Young S.T., Lukas M.A., Shusterman N.H. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996, 94(11):2793-2799.
31. Pagani M., Somers V., Furlan R., Dell'Orto S., Conway J., Baselli G., Cerutti S., Sleight P., Malliani A. Changes in autonomic regulation induced by physical training in mild hypertension. Hypertension 1988, 12(6):600-610.
32. Parati G., Saul J.P., Di R.M., Mancia G. Spectral analysis of blood pressure and heart rate variability in evaluating cardiovascular regulation. A critical appraisal. Hypertension 1995, 25(6):1276-1286.
33. Piccirillo G., Luparini R.L., Celli V., Moise A., Lionetti M., Marigliano V., Cacciafesta M. Effects of carvedilol on heart rate and blood pressure variability in subjects with chronic heart failure. Am. J. Cardiol. 2000, 86(12):1392-1395. (A6).
34. Pimentel E.B., Moraes A.C., Forechi L., Machado R.C., Baldo M.P., Mill J.G. Kinetics of the electrocardiographic changes after permanent coronary occlusion in rats: relationship with infarct size 2012.
35. Pomeranz B., Macaulay R.J., Caudill M.A., Kutz I., Adam D., Gordon D., Kilborn K.M., Barger A.C., Shannon D.C., Cohen R.J. Assessment of autonomic function in humans by heart rate spectral analysis. Am. J. Physiol. 1985, 248(1 Pt 2):H151-H153.
36. Rodrigues F.L., De O.M., Salgado H.C., Fazan R. Effect of baroreceptor denervation on the autonomic control of arterial pressure in conscious mice. Exp. Physiol. 2011, 96(9):853-862.
37. Souza H.C., Martins-Pinge M.C., Dias da Silva V.J., Borghi-Silva A., Gastaldi A.C., Blanco J.H., Tezini G.C Heart rate and arterial pressure variability in the experimental renovascular hypertension model in rats. Auton. Neurosci. 2008, 139(1-2):38-45.
38. Takagawa J., Zhang Y., Wong M.L., Sievers R.E., Kapasi N.K., Wang Y., Yeghiazarians Y., Lee R.J., Grossman W., Springer M.L. Myocardial infarct size measurement in the mouse chronic infarction model: comparison of area- and length-based approaches. J. Appl. Physiol. 2007, 102(6):2104-2111.
39. Task Force Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 1996, 93(5):1043-1065.
40. Tobaldini E., Montano N., Wei S.G., Zhang Z.H., Francis J., Weiss R.M., Casali K.R., Felder R.B., Porta A. Autonomic cardiovascular modulation. IEEE Eng. Med. Biol. Mag. 2009, 28(6):79-85.
41. Tobaldini E., Porta A., Wei S.G., Zhang Z.H., Francis J., Casali K.R., Weiss R.M., Felder R.B., Montano N. Symbolic analysis detects alterations of cardiac autonomic modulation in congestive heart failure rats. Auton. Neurosci. 2009, 150(1-2):21-26.
42. van de Borne P., Montano N., Pagani M., Oren R., Somers V.K. Absence of low-frequency variability of sympathetic nerve activity in severe heart failure. Circulation 1997, 95(6):1449-1454.
43. Watanabe K., Ohta Y., Nakazawa M., Higuchi H., Hasegawa G., Naito M., Fuse K., Ito M., Hirono S., Tanabe N., Hanawa H., Kato K., Kodama M., Aizawa Y. Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy. Br. J. Pharmacol. 2000, 130(7):1489-1495.
44. World Health Organization The global burden of disease 2004 update 2008, (Geneva).